You are here

Bid for Allergan: Morgan Stanley gets a bitter pill

Pharma firm uses bankers' emails to put further pressure on Valeant

[NEW YORK] In its quest to defend against a US$53 billion hostile takeover, Allergan pulled back the veil on the usually secretive world of mergers and acquisitions banking on Monday. Reiterating its belief that the business model of Valeant Pharmaceuticals is unsustainable, Botox-maker Allergan